{ "FullStudy":{ "Rank":217562, "Study":{ "ProtocolSection":{ "IdentificationModule":{ "NCTId":"NCT01519778", "OrgStudyIdInfo":{ "OrgStudyId":"1986-011" }, "SecondaryIdInfoList":{ "SecondaryIdInfo":[ { "SecondaryId":"TR701-126", "SecondaryIdType":"Other Identifier", "SecondaryIdDomain":"TriusRX Unique ID" } ] }, "Organization":{ "OrgFullName":"Trius Therapeutics LLC", "OrgClass":"INDUSTRY" }, "BriefTitle":"A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study", "OfficialTitle":"Phase 2 Open-Label Safety and Exploratory Skin Lesion Measurement Study of 6-Day Oral TR-701 FA in Skin Abscess and Cellulitis Patients" }, "StatusModule":{ "StatusVerifiedDate":"July 2018", "OverallStatus":"Completed", "ExpandedAccessInfo":{ "HasExpandedAccess":"No" }, "StartDateStruct":{ "StartDate":"February 15, 2012", "StartDateType":"Actual" }, "PrimaryCompletionDateStruct":{ "PrimaryCompletionDate":"August 27, 2012", "PrimaryCompletionDateType":"Actual" }, "CompletionDateStruct":{ "CompletionDate":"August 27, 2012", "CompletionDateType":"Actual" }, "StudyFirstSubmitDate":"January 24, 2012", "StudyFirstSubmitQCDate":"January 26, 2012", "StudyFirstPostDateStruct":{ "StudyFirstPostDate":"January 27, 2012", "StudyFirstPostDateType":"Estimate" }, "ResultsFirstSubmitDate":"February 27, 2015", "ResultsFirstSubmitQCDate":"February 27, 2015", "ResultsFirstPostDateStruct":{ "ResultsFirstPostDate":"March 12, 2015", "ResultsFirstPostDateType":"Estimate" }, "DispFirstSubmitDate":"April 2, 2014", "DispFirstSubmitQCDate":"April 2, 2014", "DispFirstPostDateStruct":{ "DispFirstPostDate":"April 30, 2014", "DispFirstPostDateType":"Estimate" }, "LastUpdateSubmitDate":"July 31, 2018", "LastUpdatePostDateStruct":{ "LastUpdatePostDate":"August 29, 2018", "LastUpdatePostDateType":"Actual" } }, "SponsorCollaboratorsModule":{ "ResponsibleParty":{ "ResponsiblePartyType":"Sponsor" }, "LeadSponsor":{ "LeadSponsorName":"Trius Therapeutics LLC", "LeadSponsorClass":"INDUSTRY" }, "CollaboratorList":{ "Collaborator":[ { "CollaboratorName":"Bayer", "CollaboratorClass":"INDUSTRY" } ] } }, "OversightModule":{ "OversightHasDMC":"No" }, "DescriptionModule":{ "BriefSummary":"Characterization of the safety profile of TR-701 Free Acid (FA) in patients with major cutaneous abscess or cellulitis/erysipelas.", "DetailedDescription":"This is an open-label, multicenter study of oral TR-701 FA 200 mg once daily for 6 days for the treatment of major cutaneous abscess or cellulitis/erysipelas in patients 18 years of age or older. This study is designed to further characterize the safety profile and gather additional lesion measurement data of TR-701 FA in patients with major cutaneous abscess or cellulitis/erysipelas." }, "ConditionsModule":{ "ConditionList":{ "Condition":[ "Major Cutaneous Abscess", "Cellulitis", "Erysipelas" ] } }, "DesignModule":{ "StudyType":"Interventional", "PhaseList":{ "Phase":[ "Phase 2" ] }, "DesignInfo":{ "DesignInterventionModel":"Single Group Assignment", "DesignPrimaryPurpose":"Other", "DesignMaskingInfo":{ "DesignMasking":"None (Open Label)" } }, "EnrollmentInfo":{ "EnrollmentCount":"200", "EnrollmentType":"Actual" } }, "ArmsInterventionsModule":{ "ArmGroupList":{ "ArmGroup":[ { "ArmGroupLabel":"TR-701 FA", "ArmGroupType":"Experimental", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: TR701 FA" ] } } ] }, "InterventionList":{ "Intervention":[ { "InterventionType":"Drug", "InterventionName":"TR701 FA", "InterventionDescription":"1 tablet 200 mg once daily", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "TR-701 FA" ] }, "InterventionOtherNameList":{ "InterventionOtherName":[ "Tedizolid" ] } } ] } }, "OutcomesModule":{ "PrimaryOutcomeList":{ "PrimaryOutcome":[ { "PrimaryOutcomeMeasure":"Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)", "PrimaryOutcomeDescription":"Safety will be assessed through summaries of the incidence of AEs and SAEs as well as through summaries of vital signs, physical examinations, ECG findings, and laboratory assessments (hematology, serum chemistry, and urinalysis).", "PrimaryOutcomeTimeFrame":"24-31 days" } ] } }, "EligibilityModule":{ "EligibilityCriteria":"Inclusion Criteria:\n\nMale or female patients ≥ 18 years of age\nSuspected or documented gram-positive infection from baseline Gram stain or culture.\nCellulitis/erysipelas or major cutaneous abscesses at Screening\n\nExclusion Criteria:\n\nPostsurgical or open wound infections\nSevere sepsis or septic shock\nUncomplicated skin and skin structure infections such as furuncles, minor abscesses (< 75 cm2 or area of suppuration not surrounded by cellulitis/erythema), and impetiginous lesions\nInfections associated with, or in close proximity to, a prosthetic device\nKnown bacteremia or osteomyelitis at time of screening", "HealthyVolunteers":"No", "Gender":"All", "MinimumAge":"18 Years", "StdAgeList":{ "StdAge":[ "Adult", "Older Adult" ] } }, "ContactsLocationsModule":{ "OverallOfficialList":{ "OverallOfficial":[ { "OverallOfficialName":"Philippe Prokocimer, MD", "OverallOfficialAffiliation":"Trius Therapeutics", "OverallOfficialRole":"Study Chair" } ] }, "LocationList":{ "Location":[ { "LocationFacility":"Trius Investigator Site #118", "LocationCity":"Anaheim", "LocationState":"California", "LocationZip":"92804", "LocationCountry":"United States" },{ "LocationFacility":"Trius Investigator Site #129", "LocationCity":"Buena Park", "LocationState":"California", "LocationZip":"90620", "LocationCountry":"United States" },{ "LocationFacility":"Trius Investigator Site 103", "LocationCity":"Chula Vista", "LocationState":"California", "LocationZip":"91911", "LocationCountry":"United States" },{ "LocationFacility":"Trius Investigator Site 105", "LocationCity":"La Mesa", "LocationState":"California", "LocationZip":"91942", "LocationCountry":"United States" },{ "LocationFacility":"Trius Investigator Site #106", "LocationCity":"Long Beach", "LocationState":"California", "LocationZip":"90813", "LocationCountry":"United States" },{ "LocationFacility":"Trius Investigator Site 104", "LocationCity":"Oceanside", "LocationState":"California", "LocationZip":"92056", "LocationCountry":"United States" },{ "LocationFacility":"Trius Investigator Site 101", "LocationCity":"Columbus", "LocationState":"Georgia", "LocationZip":"31904", "LocationCountry":"United States" },{ "LocationFacility":"Trius Investigator Site 102", "LocationCity":"Savannah", "LocationState":"Georgia", "LocationZip":"31406", "LocationCountry":"United States" },{ "LocationFacility":"Trius Investigator Site 128", "LocationCity":"Las Vegas", "LocationState":"Nevada", "LocationZip":"89109", "LocationCountry":"United States" },{ "LocationFacility":"Trius Investigator Site 115", "LocationCity":"Somers Point", "LocationState":"New Jersey", "LocationZip":"08244", "LocationCountry":"United States" } ] } }, "ReferencesModule":{ "ReferenceList":{ "Reference":[ { "ReferencePMID":"27530088", "ReferenceType":"result", "ReferenceCitation":"Powers JH 3rd, Das AF, De Anda C, Prokocimer P. Clinician-reported lesion measurements in skin infection trials: Definitions, reliability, and association with patient-reported pain. Contemp Clin Trials. 2016 Sep;50:265-72. doi: 10.1016/j.cct.2016.08.010. Epub 2016 Aug 13." } ] } }, "IPDSharingStatementModule":{ "IPDSharing":"Yes", "IPDSharingDescription":"https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf", "IPDSharingURL":"http://engagezone.msd.com/ds_documentation.php" } }, "ResultsSection":{ "ParticipantFlowModule":{ "FlowGroupList":{ "FlowGroup":[ { "FlowGroupId":"FG000", "FlowGroupTitle":"TR-701 FA", "FlowGroupDescription":"TR701 FA: 1 tablet 200 mg once daily" } ] }, "FlowPeriodList":{ "FlowPeriod":[ { "FlowPeriodTitle":"Overall Study", "FlowMilestoneList":{ "FlowMilestone":[ { "FlowMilestoneType":"STARTED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"200" } ] } },{ "FlowMilestoneType":"COMPLETED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"186" } ] } },{ "FlowMilestoneType":"NOT COMPLETED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"14" } ] } } ] }, "FlowDropWithdrawList":{ "FlowDropWithdraw":[ { "FlowDropWithdrawType":"Withdrawal by Subject", "FlowReasonList":{ "FlowReason":[ { "FlowReasonGroupId":"FG000", "FlowReasonNumSubjects":"3" } ] } },{ "FlowDropWithdrawType":"Lost to Follow-up", "FlowReasonList":{ "FlowReason":[ { "FlowReasonGroupId":"FG000", "FlowReasonNumSubjects":"10" } ] } },{ "FlowDropWithdrawType":"Physician Decision", "FlowReasonList":{ "FlowReason":[ { "FlowReasonGroupId":"FG000", "FlowReasonNumSubjects":"1" } ] } } ] } } ] } }, "BaselineCharacteristicsModule":{ "BaselineGroupList":{ "BaselineGroup":[ { "BaselineGroupId":"BG000", "BaselineGroupTitle":"TR-701 FA", "BaselineGroupDescription":"TR701 FA: 1 tablet 200 mg once daily" } ] }, "BaselineDenomList":{ "BaselineDenom":[ { "BaselineDenomUnits":"Participants", "BaselineDenomCountList":{ "BaselineDenomCount":[ { "BaselineDenomCountGroupId":"BG000", "BaselineDenomCountValue":"200" } ] } } ] }, "BaselineMeasureList":{ "BaselineMeasure":[ { "BaselineMeasureTitle":"Age, Continuous", "BaselineMeasureParamType":"Mean", "BaselineMeasureDispersionType":"Standard Deviation", "BaselineMeasureUnitOfMeasure":"years", "BaselineClassList":{ "BaselineClass":[ { "BaselineCategoryList":{ "BaselineCategory":[ { "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"39.5", "BaselineMeasurementSpread":"13.04" } ] } } ] } } ] } },{ "BaselineMeasureTitle":"Sex: Female, Male", "BaselineMeasureParamType":"Count of Participants", "BaselineMeasureUnitOfMeasure":"Participants", "BaselineClassList":{ "BaselineClass":[ { "BaselineCategoryList":{ "BaselineCategory":[ { "BaselineCategoryTitle":"Female", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"71" } ] } },{ "BaselineCategoryTitle":"Male", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"129" } ] } } ] } } ] } } ] } }, "OutcomeMeasuresModule":{ "OutcomeMeasureList":{ "OutcomeMeasure":[ { "OutcomeMeasureType":"Primary", "OutcomeMeasureTitle":"Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)", "OutcomeMeasureDescription":"Safety will be assessed through summaries of the incidence of AEs and SAEs as well as through summaries of vital signs, physical examinations, ECG findings, and laboratory assessments (hematology, serum chemistry, and urinalysis).", "OutcomeMeasurePopulationDescription":"Patients receiving any amount of study drug", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"participants", "OutcomeMeasureTimeFrame":"24-31 days", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"TR-701 FA", "OutcomeGroupDescription":"TR701 FA: 1 tablet 200 mg once daily" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"200" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"91" } ] } } ] } } ] } } ] } }, "AdverseEventsModule":{ "EventsFrequencyThreshold":"2", "EventsTimeFrame":"From the Informed Consent Form signature through the late follow-up visit, up to 32 days.", "EventGroupList":{ "EventGroup":[ { "EventGroupId":"EG000", "EventGroupTitle":"TR-701 FA", "EventGroupDescription":"TR701 FA: 1 tablet 200 mg once daily", "EventGroupSeriousNumAffected":"2", "EventGroupSeriousNumAtRisk":"200", "EventGroupOtherNumAffected":"58", "EventGroupOtherNumAtRisk":"200" } ] }, "SeriousEventList":{ "SeriousEvent":[ { "SeriousEventTerm":"hemoptysis", "SeriousEventOrganSystem":"Respiratory, thoracic and mediastinal disorders", "SeriousEventSourceVocabulary":"MedDRA 13.1", "SeriousEventAssessmentType":"Systematic Assessment", "SeriousEventStatsList":{ "SeriousEventStats":[ { "SeriousEventStatsGroupId":"EG000", "SeriousEventStatsNumAffected":"1", "SeriousEventStatsNumAtRisk":"200" } ] } },{ "SeriousEventTerm":"thrombophlebitis septic", "SeriousEventOrganSystem":"Infections and infestations", "SeriousEventSourceVocabulary":"MedDRA 13.1", "SeriousEventAssessmentType":"Systematic Assessment", "SeriousEventStatsList":{ "SeriousEventStats":[ { "SeriousEventStatsGroupId":"EG000", "SeriousEventStatsNumAffected":"1", "SeriousEventStatsNumAtRisk":"200" } ] } } ] }, "OtherEventList":{ "OtherEvent":[ { "OtherEventTerm":"Nausea", "OtherEventOrganSystem":"Gastrointestinal disorders", "OtherEventSourceVocabulary":"MedDRA 13.1", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"22", "OtherEventStatsNumAtRisk":"200" } ] } },{ "OtherEventTerm":"diarrhea", "OtherEventOrganSystem":"Gastrointestinal disorders", "OtherEventSourceVocabulary":"MedDRA 13.1", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"13", "OtherEventStatsNumAtRisk":"200" } ] } },{ "OtherEventTerm":"cellulitis", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 13.1", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"10", "OtherEventStatsNumAtRisk":"200" } ] } },{ "OtherEventTerm":"abscess", "OtherEventOrganSystem":"Infections and infestations", "OtherEventSourceVocabulary":"MedDRA 13.1", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"9", "OtherEventStatsNumAtRisk":"200" } ] } },{ "OtherEventTerm":"vomiting", "OtherEventOrganSystem":"Gastrointestinal disorders", "OtherEventSourceVocabulary":"MedDRA 13.1", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"9", "OtherEventStatsNumAtRisk":"200" } ] } },{ "OtherEventTerm":"dizziness", "OtherEventOrganSystem":"Nervous system disorders", "OtherEventSourceVocabulary":"MedDRA 13.1", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"7", "OtherEventStatsNumAtRisk":"200" } ] } },{ "OtherEventTerm":"headache", "OtherEventOrganSystem":"Nervous system disorders", "OtherEventSourceVocabulary":"MedDRA 13.1", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"7", "OtherEventStatsNumAtRisk":"200" } ] } },{ "OtherEventTerm":"chills", "OtherEventOrganSystem":"General disorders", "OtherEventSourceVocabulary":"MedDRA 13.1", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"4", "OtherEventStatsNumAtRisk":"200" } ] } },{ "OtherEventTerm":"constipation", "OtherEventOrganSystem":"Gastrointestinal disorders", "OtherEventSourceVocabulary":"MedDRA 13.1", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"4", "OtherEventStatsNumAtRisk":"200" } ] } },{ "OtherEventTerm":"somnolence", "OtherEventOrganSystem":"Nervous system disorders", "OtherEventSourceVocabulary":"MedDRA 13.1", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"4", "OtherEventStatsNumAtRisk":"200" } ] } } ] } }, "MoreInfoModule":{ "CertainAgreement":{ "AgreementPISponsorEmployee":"No", "AgreementRestrictionType":"OTHER", "AgreementRestrictiveAgreement":"Yes", "AgreementOtherDetails":"Trius intends to pursue publication of the results of the study in cooperation with a lead Investigator, subject to the terms and conditions of the clinical study agreement between Trius and Investigators. Trius written approval is required for publication of any data subsets. Final authorship will be determined in accordance with the International Conference of Medical Journal Editors definition of authorship." }, "PointOfContact":{ "PointOfContactTitle":"Carisa De Anda, Phd, Vice President Clinical Research", "PointOfContactOrganization":"Cubist Pharmaceuticals", "PointOfContactEMail":"carisa.deanda@cubist.com", "PointOfContactPhone":"8583522639" } } }, "DerivedSection":{ "MiscInfoModule":{ "VersionHolder":"April 22, 2020" }, "InterventionBrowseModule":{ "InterventionMeshList":{ "InterventionMesh":[ { "InterventionMeshId":"C000546016", "InterventionMeshTerm":"Tedizolid" } ] }, "InterventionAncestorList":{ "InterventionAncestor":[ { "InterventionAncestorId":"D000000900", "InterventionAncestorTerm":"Anti-Bacterial Agents" },{ "InterventionAncestorId":"D000000890", "InterventionAncestorTerm":"Anti-Infective Agents" } ] }, "InterventionBrowseLeafList":{ "InterventionBrowseLeaf":[ { "InterventionBrowseLeafId":"M275580", "InterventionBrowseLeafName":"Tedizolid phosphate", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M275579", "InterventionBrowseLeafName":"Tedizolid", "InterventionBrowseLeafAsFound":"Tedizolid", "InterventionBrowseLeafRelevance":"high" },{ "InterventionBrowseLeafId":"M2803", "InterventionBrowseLeafName":"Anti-Bacterial Agents", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M2795", "InterventionBrowseLeafName":"Anti-Infective Agents", "InterventionBrowseLeafRelevance":"low" } ] }, "InterventionBrowseBranchList":{ "InterventionBrowseBranch":[ { "InterventionBrowseBranchAbbrev":"Infe", "InterventionBrowseBranchName":"Anti-Infective Agents" },{ "InterventionBrowseBranchAbbrev":"All", "InterventionBrowseBranchName":"All Drugs and Chemicals" } ] } }, "ConditionBrowseModule":{ "ConditionMeshList":{ "ConditionMesh":[ { "ConditionMeshId":"D000000038", "ConditionMeshTerm":"Abscess" },{ "ConditionMeshId":"D000002481", "ConditionMeshTerm":"Cellulitis" },{ "ConditionMeshId":"D000004886", "ConditionMeshTerm":"Erysipelas" } ] }, "ConditionAncestorList":{ "ConditionAncestor":[ { "ConditionAncestorId":"D000013492", "ConditionAncestorTerm":"Suppuration" },{ "ConditionAncestorId":"D000007239", "ConditionAncestorTerm":"Infection" },{ "ConditionAncestorId":"D000007249", "ConditionAncestorTerm":"Inflammation" },{ "ConditionAncestorId":"D000010335", "ConditionAncestorTerm":"Pathologic Processes" },{ "ConditionAncestorId":"D000012874", "ConditionAncestorTerm":"Skin Diseases, Infectious" },{ "ConditionAncestorId":"D000003240", "ConditionAncestorTerm":"Connective Tissue Diseases" },{ "ConditionAncestorId":"D000013290", "ConditionAncestorTerm":"Streptococcal Infections" },{ "ConditionAncestorId":"D000016908", "ConditionAncestorTerm":"Gram-Positive Bacterial Infections" },{ "ConditionAncestorId":"D000001424", "ConditionAncestorTerm":"Bacterial Infections" },{ "ConditionAncestorId":"D000017192", "ConditionAncestorTerm":"Skin Diseases, Bacterial" },{ "ConditionAncestorId":"D000012871", "ConditionAncestorTerm":"Skin Diseases" } ] }, "ConditionBrowseLeafList":{ "ConditionBrowseLeaf":[ { "ConditionBrowseLeafId":"M4313", "ConditionBrowseLeafName":"Cellulitis", "ConditionBrowseLeafAsFound":"Cellulitis", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M37", "ConditionBrowseLeafName":"Abscess", "ConditionBrowseLeafAsFound":"Abscess", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M6623", "ConditionBrowseLeafName":"Erysipelas", "ConditionBrowseLeafAsFound":"Erysipelas", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M14856", "ConditionBrowseLeafName":"Suppuration", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M8866", "ConditionBrowseLeafName":"Infection", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M4951", "ConditionBrowseLeafName":"Communicable Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M8876", "ConditionBrowseLeafName":"Inflammation", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M14257", "ConditionBrowseLeafName":"Skin Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M14260", "ConditionBrowseLeafName":"Skin Diseases, Infectious", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M5047", "ConditionBrowseLeafName":"Connective Tissue Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M14663", "ConditionBrowseLeafName":"Streptococcal Infections", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M3303", "ConditionBrowseLeafName":"Bacterial Infections", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M17835", "ConditionBrowseLeafName":"Gram-Positive Bacterial Infections", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M18083", "ConditionBrowseLeafName":"Skin Diseases, Bacterial", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"T2141", "ConditionBrowseLeafName":"Erysipelas", "ConditionBrowseLeafAsFound":"Erysipelas", "ConditionBrowseLeafRelevance":"high" } ] }, "ConditionBrowseBranchList":{ "ConditionBrowseBranch":[ { "ConditionBrowseBranchAbbrev":"BC01", "ConditionBrowseBranchName":"Bacterial and Fungal Diseases" },{ "ConditionBrowseBranchAbbrev":"BC17", "ConditionBrowseBranchName":"Skin and Connective Tissue Diseases" },{ "ConditionBrowseBranchAbbrev":"BC23", "ConditionBrowseBranchName":"Symptoms and General Pathology" },{ "ConditionBrowseBranchAbbrev":"All", "ConditionBrowseBranchName":"All Conditions" },{ "ConditionBrowseBranchAbbrev":"Rare", "ConditionBrowseBranchName":"Rare Diseases" } ] } } } } } }